H.C. Wainwright raised the firm’s price target on TG Therapeutics (TGTX) to $55 from $49 and keeps a Buy rating on the shares. TG Therapeutics reported Q3 results, including “solid” Briumvi U.S. net product revenue up $83.3M, up 15% quarter over quarter, the analyst tells investors in a research note. The firm projects 2028 revenues of $814M for Briumvi in multiple sclerosis in the U.S. and European Briumvi sales of $141M in 2028, translating to potential royalties of $29.5M to TG.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TGTX:
- Morning Movers: Air Transport Services jumps following $3.1B take-private deal
- TG Therapeutics reports Q3 EPS 2c, consensus 3c
- TG Therapeutics sees FY24 BRIUMVI U.S. revenue target $300M-$305M
- TGTX Earnings this Week: How Will it Perform?
- TG Therapeutics initiated with a Buy at TD Cowen
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
